Avastin.net
skip to the content
Search
Search
Home
Avastin MoA
Understanding the Avastin MoA
Avastin regresses vasculature
Regression increases tumour response
Avastin normalises vasculature
Normalisation maximises efficacy
Avastin inhibits vessel growth
Inhibition provides continued disease control
Summary
References
Avastin controls tumour growth
Efficacy of Avastin
Efficacy across tumours
Avastin provides benefit in several tumour types
Why search for a biomarker?
The search for a predictive biomarker
All patient subgroups can benefit
Combinability with a range of therapies
Conventional chemotherapy
Other treatment modalities
Summary
References
Optimal duration of Avastin therapy
Treatment until PD
Summary
References
Limits toxicity
The safety profile of Avastin
The safety profile of Avastin does not overlap
Summary
References
Avastin in NSCLC
First-line treatment
AVF0757g
Efficacy
Safety
ECOG 4599
OS
PFS and ORR
OS in adenocarcinoma
Patient subgroups
Safety
AVAiL
PFS
PFS in maintenance
Patient subgroups
ORR
Safety
SAiL
Safety
AEs of special interest
Efficacy
Efficacy in the elderly
ARIES
Preliminary results
Extending the benefit
Waples, et al.
Patel, et al.
AVAPERL1
PointBreak
ATLAS
BeTa lung
Additional areas of investigation
Summary
References
Labelling information
Slide decks and videos
Visit Science of VEGF
Sitemap
Contact
Abbreviations
Home
Avastin MoA
Understanding the Avastin MoA
Avastin regresses vasculature
Regression increases tumour response
Avastin normalises vasculature
Normalisation maximises efficacy
Avastin inhibits vessel growth
Inhibition provides continued disease control
Summary
References
Avastin controls tumour growth
Efficacy of Avastin
Efficacy across tumours
Avastin provides benefit in several tumour types
Why search for a biomarker?
The search for a predictive biomarker
All patient subgroups can benefit
Combinability with a range of therapies
Conventional chemotherapy
Other treatment modalities
Summary
References
Optimal duration of Avastin therapy
Treatment until PD
Summary
References
Limits toxicity
The safety profile of Avastin
The safety profile of Avastin does not overlap
Summary
References
Avastin in NSCLC
First-line treatment
AVF0757g
Efficacy
Safety
ECOG 4599
OS
PFS and ORR
OS in adenocarcinoma
Patient subgroups
Safety
AVAiL
PFS
PFS in maintenance
Patient subgroups
ORR
Safety
SAiL
Safety
AEs of special interest
Efficacy
Efficacy in the elderly
ARIES
Preliminary results
Extending the benefit
Waples, et al.
Patel, et al.
AVAPERL1
PointBreak
ATLAS
BeTa lung
Additional areas of investigation
Summary
References
Labelling information
Slide decks and videos
Visit Science of VEGF